ミズーリ州における脂肪肝の臨床試験
ミズーリ州内の拠点で、脂肪肝に関する14件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, St Louis
- 89bio Clinical Study Site, St Louis
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/10/05更新 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, St Louis
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/10/05更新 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/30更新 · NCT07701993A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Washington University School of Medicine, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- AMR Clinical, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Columbia
- Akero Clinical Study Site, Kansas City
- Akero Clinical Study Site, St Louis
- 他1件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
- GSK Investigational Site, St Louis
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Gastrointestinal Associates, Columbia
- Gateway GI Research, LLC, St Louis
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/09更新 · NCT07288138Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
- University of Missouri School of Medicine, Columbia
被験者募集中観察研究健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/08/06更新 · NCT06571474Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
- University of Missouri School of Medicine, Columbia
被験者募集中健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/08/06更新 · NCT06335771A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Kansas City
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Kansas City
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/07/08更新 · NCT06920043Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- Harry S. Truman Memorial, Columbia, MO, Columbia
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/02/19更新 · NCT05526144ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。